研究実績
1999年以前の研究実績はこちら
著 書
論 文
- Sakakibara O, Shimoda M, Yamamoto G, Higashi Y, Ikeda-Imafuku M, Ishima Y, Kawahara M, Tanaka KI.Effectiveness of Albumin-Fused Thioredoxin against 6-Hydroxydopamine-Induced Neurotoxicity In Vitro.Int J Mol Sci. 2023 Jun 5;24(11):9758. doi: 10.3390/ijms24119758.
- Ibrahim M, Shimizu T, Ando H, Ishima Y, Elgarhy OH, Sarhan HA, Hussein AK, Ishida T. Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. J Control Release. 2023 Feb;354:260-267. doi: 10.1016/j.jconrel.2023.01.012. Epub 2023 Jan 12.
- Yasuda K, Maeda H, Kinoshita R, Minayoshi Y, Mizuta Y, Nakamura Y, Imoto S, Nishi K, Yamasaki K, Sakuragi M, Nakamura T, Ikeda-Imafuku M, Iwao Y, Ishima Y, Ishida T, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis. ACS Nano. 2023 Sep 12;17(17):16668-16681. doi: 10.1021/acsnano.3c02877. Epub 2023 Aug 14.
- Shimizu T, Matsuzaki T, Fukuda S, Yoshioka C, Shimazaki Y, Takese S, Yamanaka K, Nakae T, Ishibashi M, Hamamoto H, Ando H, Ishima Y, Ishida T.Ionic Liquid-Based Transcutaneous Peptide Antitumor Vaccine: Therapeutic Effect in a Mouse Tumor Model. AAPS J. 2023 Feb 17;25(2):27. doi: 10.1208/s12248-023-00790-w.
- Takata H, Shimizu T, Yamade R, Elsadek NE, Emam SE, Ando H, Ishima Y, Ishida T. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.J Control Release. 2023 Aug;360:285-292. doi: 10.1016/j.jconrel.2023.06.027. Epub 2023 Jun 29.
- Katsumi H, Morishita M, Yamamoto A. Development of Serine Modification-based Kidney-targeted Drug Delivery System. Yakugaku Zasshi. 2023;143(2):121-126. doi: 10.1248/yakushi.22-00156-1.
- Morishita M, Katsumi H, Yamamoto A. Effect of Probiotic-derived Extracellular Vesicles on Innate Immunity and Their Usability.Yakugaku Zasshi. 2023;143(4):365-368. doi: 10.1248/yakushi.22-00170-5.
- Higuchi A, Morishita M, Nagata R, Maruoka K, Katsumi H, Yamamoto A. Functional Characterization of Extracellular Vesicles from Baker's Yeast Saccharomyces Cerevisiae as a Novel Vaccine Material for Immune Cell Maturation. J Pharm Sci. 2023 Feb;112(2):525-534. doi: 10.1016/j.xphs.2022.08.032. Epub 2022 Aug 31.
- Morishita M, Nagata R, Maruoka K, Higuchi A, Sasaki S, Wada S, Katsumi H, Yamamoto A. Lymphatic Transport and Immune Activation Effect by Locally Administered Extracellular Vesicles from Saccharomyces cerevisiae as Biocompatible Vaccine Adjuvants. Biol Pharm Bull. 2023;46(10):1427-1434. doi: 10.1248/bpb.b23-00282.